Enanta Pharmaceuticals (ENTA) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 23, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Aug 12, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ENTA SEC filings page.
Enanta Pharmaceuticals, Inc (ENTA) reported $65.3M in revenue over the twelve months to Jun 30, 2026, up 0.7% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Enanta remains a development-stage business: reduced research spending narrowed cash use, while liabilities now finance most of a shrinking asset base.
FY2025 operating cash flow was-$19.3M against a net loss of$81.9M , so accounting loss and cash use diverged materially. After$12.9M of capital expenditures, free cash flow was-$32.2M , showing that reinvestment still consumes cash even as operating cash use improved.
With revenue at
Liabilities were
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Enanta Pharmaceuticals, Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Enanta Pharmaceuticals, Inc held $188.9M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $19.3M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Enanta Pharmaceuticals, Inc scores 79/100 among other emerging companies.
Enanta Pharmaceuticals, Inc had 29M shares outstanding at the end of fiscal year 2025, against 21M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Enanta Pharmaceuticals, Inc scores 39/100 among other emerging companies.
Enanta Pharmaceuticals, Inc spent $106.7M on research and development in fiscal year 2025, which was 70.8% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Enanta Pharmaceuticals, Inc scores 90/100 among other emerging companies.
Enanta Pharmaceuticals, Inc reported revenue of $65.3M in fiscal year 2025, against $67.6M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Enanta Pharmaceuticals, Inc scores 32/100 among other emerging companies.
Enanta Pharmaceuticals, Inc's operations used $19.3M of cash in fiscal year 2025, against $78.8M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Enanta Pharmaceuticals, Inc scores 86/100 among other emerging companies.
Enanta Pharmaceuticals, Inc's cash, cash equivalents and investments came to $188.9M at the end of fiscal year 2025, against $216.0M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Enanta Pharmaceuticals, Inc scores 57/100 among other emerging companies.
Enanta Pharmaceuticals, Inc scores -1.18, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $404.9M against total assets of $280.7M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Enanta Pharmaceuticals, Inc passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), the one computable operating efficiency signal (asset turnover improving) passes.
Enanta Pharmaceuticals, Inc reported a net loss of $81.9M while operations used $19.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Enanta Pharmaceuticals, Inc reported an operating loss of $85.3M against $7.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Enanta Pharmaceuticals, Inc generated $14.4M in revenue in Q3 2026. This represents a decrease of 21.6% from the same quarter a year earlier. Against the prior quarter it is down 16.3%.
Enanta Pharmaceuticals, Inc's EBITDA was -$16.1M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Enanta Pharmaceuticals, Inc reported a net loss of $19.5M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Enanta Pharmaceuticals, Inc earned -$0.67 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cash & Balance Sheet
Enanta Pharmaceuticals, Inc recorded an outflow of $10.0M in free cash flow in Q3 2026, representing a cash shortfall after capex. This represents a decrease of 157.5% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Enanta Pharmaceuticals, Inc held $33.4M in cash as of Q3 2026; no long-term debt figure is on record for that period.
Not reported for Q3 2026.
Margins & Returns
Enanta Pharmaceuticals, Inc's quarterly ROE was -19.3% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is up 3.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 8.1 percentage points.
Not reported for Q3 2026.
Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Enanta Pharmaceuticals, Inc invested $22.1M in research and development in Q3 2026. This represents a decrease of 18.7% from the same quarter a year earlier. Against the prior quarter it is up 13.8%.
Enanta Pharmaceuticals, Inc invested $7K in capex in Q3 2026, funding long-term assets and infrastructure. This represents a decrease of 95.5% from the same quarter a year earlier. Against the prior quarter it is down 53.3%.
Not reported for Q3 2026.
ENTA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14.4M-21.6% | $17.2M+15.0% | $18.6M+9.8% | $15.1M+3.5% | $18.3M+1.9% | $14.9M-12.5% | $17.0M-5.8% | $14.6M-22.8% |
| R&D Expenses | $22.1M-18.7% | $19.4M-30.7% | $20.9M-24.6% | $23.8M-22.6% | $27.2M-5.3% | $28.1M-21.1% | $27.7M-24.0% | $30.8M-14.9% |
| SG&A Expenses | $9.5M-5.3% | $9.6M-16.0% | $9.0M-29.9% | $9.7M-29.1% | $10.0M-25.5% | $11.4M-20.0% | $12.8M-22.2% | $13.7M-0.8% |
| Operating Income | -$17.2Mn/m | -$11.9Mn/m | -$11.3Mn/m | -$18.4Mn/m | -$18.9Mn/m | -$24.5Mn/m | -$23.5Mn/m | -$29.9Mn/m |
| EBITDA | -$16.1Mn/m | -$10.6Mn/m | -$10.0Mn/m | -$17.1Mn/m | -$17.7Mn/m | -$23.3Mn/m | -$22.7Mn/m | -$29.4Mn/m |
| Interest Expense | $4.1M+155.3% | $3.3M+93.5% | $3.1M+57.1% | $2.4M-7.5% | $1.6M-31.3% | $1.7M-33.1% | $2.0M-43.0% | $2.6M-18.1% |
| Income Tax | $36K+24.1% | $7Kn/m | $24Kn/m | $32Kn/m | $29Kn/m | -$1.3Mn/m | -$416Kn/m | -$363Kn/m |
| Net Income | -$19.5Mn/m | -$13.1Mn/m | -$11.9Mn/m | -$18.7Mn/m | -$18.3Mn/m | -$22.6Mn/m | -$22.3Mn/m | -$28.8Mn/m |
| EPS (Basic) | -$0.67n/m | -$0.45n/m | -$0.42n/m | N/A | -$0.85n/m | -$1.06n/m | -$1.05n/m | N/A |
| EPS (Diluted) | -$0.67n/m | -$0.45n/m | -$0.42n/m | N/A | -$0.85n/m | -$1.06n/m | -$1.05n/m | N/A |
| Diluted Shares (Avg) | 29M+36.1% | 29M+36.0% | 29M+35.4% | N/A | 21M+0.9% | 21M+0.9% | 21M+0.7% | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
ENTA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $296.9M-1.4% | $314.7M-2.6% | $329.5M-5.5% | $280.7M-25.5% | $301.0M-24.5% | $323.0M-21.9% | $348.6M-18.6% | $376.7M-18.5% |
| Current Assets | $203.6M-8.6% | $178.4M-26.5% | $198.7M-25.9% | $204.3M-31.9% | $222.7M-22.3% | $242.9M-30.8% | $268.1M-31.3% | $299.9M-29.1% |
| Cash & Equivalents | $33.4M-25.4% | $34.9M-42.0% | $37.4M-55.6% | $32.3M-13.3% | $44.8M+25.3% | $60.2M-5.2% | $84.3M+111.2% | $37.2M-56.4% |
| Short-Term Investments | $156.1M-2.0% | $128.8M-3.2% | $148.4M+12.1% | $156.6M-25.8% | $159.3M-18.0% | $133.2M-43.8% | $132.3M-55.5% | $211.0M-25.9% |
| Accounts Receivable | $6.5M-21.6% | $7.8M+15.0% | $8.5M+10.0% | $6.9M+3.6% | $8.3M+1.9% | $6.8M-12.4% | $7.7M-5.6% | $6.6M-22.8% |
| Long-Term Investments | $22.0Mn/m | $63.2Mn/m | $56.1Mn/m | $0n/m | $0-100.0% | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $195.8M-11.7% | $198.1M-13.7% | $202.9M-14.3% | $216.0M-12.8% | $221.8M-11.3% | $229.5M-7.3% | $236.8M+0.1% | $247.8M+0.9% |
| Current Liabilities | $54.2M+21.6% | $46.4M+1.1% | $44.7M-8.8% | $48.6M-15.6% | $44.5M-23.5% | $45.9M-15.9% | $49.0M-21.4% | $57.5M-8.4% |
| Non-Current Liabilities | $141.6M-20.1% | $151.7M-17.3% | $158.2M-15.8% | $167.5M-12.0% | $177.2M-7.6% | $183.5M-4.8% | $187.8M+7.8% | $190.3M+4.1% |
| Total Equity | $101.1M+27.5% | $116.6M+24.6% | $126.6M+13.2% | $64.7M-49.8% | $79.3M-46.8% | $93.5M-43.7% | $111.8M-41.7% | $128.8M-40.6% |
| Retained Earnings | -$449.5Mn/m | -$430.0Mn/m | -$416.9Mn/m | -$404.9Mn/m | -$386.2Mn/m | -$368.0Mn/m | -$345.3Mn/m | -$323.0Mn/m |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
ENTA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$10.0M-157.0% | -$7.2Mn/m | -$11.7Mn/m | -$6.5Mn/m | $17.5Mn/m | -$13.5Mn/m | -$16.8Mn/m | -$10.4Mn/m |
| Depreciation & Amortization | $1.2M-2.1% | $1.2M+0.5% | $1.2M+38.4% | $1.3M+168.1% | $1.2M+103.7% | $1.2M+93.7% | $889K+38.5% | $479K-28.4% |
| Stock-Based Compensation | $3.7M-11.8% | $3.7M-20.1% | $3.8M-32.8% | N/A | $4.2M-22.9% | $4.7M-15.7% | $5.7M-30.0% | N/A |
| Capital Expenditures | $7K-95.5% | $15K-99.4% | $143K-98.4% | $1.5M-83.7% | $155K-97.6% | $2.5M+52.2% | $8.7M+1011.2% | $9.0M+554.3% |
| Free Cash Flow | -$10.0M-157.5% | -$7.2Mn/m | -$11.8Mn/m | -$7.9Mn/m | $17.4Mn/m | -$16.0Mn/m | -$25.5Mn/m | -$19.4Mn/m |
| Investing Cash Flow | $14.0Mn/m | $11.9Mn/m | -$47.3M-168.6% | $2.3M-88.0% | -$26.5Mn/m | -$4.4M-107.5% | $68.9Mn/m | $19.1M+61.1% |
| Financing Cash Flow | -$5.5Mn/m | -$7.3Mn/m | $64.1Mn/m | -$8.3Mn/m | -$6.4Mn/m | -$6.9Mn/m | -$5.0Mn/m | -$7.2Mn/m |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
ENTA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -120.0% | -69.1% | -60.5% | -121.6% | -103.2% | -164.3% | -138.8% | -204.4% |
| Net Margin | -135.8% | -76.3% | -64.1% | -123.6% | -99.7% | -151.7% | -131.4% | -197.3% |
| Return on Equity | -19.3%+3.7pp | -11.2%+13.0pp | -9.4%+10.5pp | -28.9%-6.5pp | -23.0%-7.8pp | -24.2%-5.5pp | -19.9%-2.5pp | -22.4%-9.4pp |
| Return on Assets | -6.6%-0.5pp | -4.2%+2.8pp | -3.6%+2.8pp | -6.7%+1.0pp | -6.1%-0.4pp | -7.0%+0.5pp | -6.4%+1.4pp | -7.6%-1.6pp |
| Current Ratio | 3.76-1.2x | 3.84-1.4x | 4.44-1.0x | 4.21-1.0x | 5.00+0.1x | 5.29-1.1x | 5.47-0.8x | 5.21-1.5x |
| Liabilities-to-Equity | 1.94-0.9x | 1.70-0.8x | 1.60-0.5x | 3.34+1.4x | 2.80+1.1x | 2.45+1.0x | 2.12+0.9x | 1.92+0.8x |
| Asset Turnover | 0.050.0x | 0.050.0x | 0.060.0x | 0.050.0x | 0.060.0x | 0.050.0x | 0.050.0x | 0.040.0x |
| FCF Margin | -69.5%-164.2pp | -41.8% | -63.6% | -52.5% | 94.7% | -107.4% | -150.6% | -132.5% |
Not reported in any period shown, so not listed: Gross Margin, Debt-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Enanta Pharmaceuticals, Inc ENTA | FY2025 | $65.3M | -$81.9M | N/A | $339.0M | 64/100 |
| Innate Pharma S.A. IPHA | FY2025 | $10.6M | -$57.7M | N/A | $167.6M | 42/100 |
| SELLAS Life Sciences Group, Inc. SLS | FY2025 | N/A | -$26.9M | N/A | $2.3B | — |
| NeOnc Technologies Holdings, Inc. NTHI | FY2025 | $40K | N/A | N/A | $94.2M | — |
| Kyverna Therapeutics, Inc. KYTX | FY2025 | N/A | -$161.3M | N/A | $333.3M | — |
Where Enanta Pharmaceuticals, Inc Ranks
Frequently Asked Questions
What is Enanta Pharmaceuticals, Inc's annual revenue?
Enanta Pharmaceuticals, Inc (ENTA) reported $65.3M in total revenue for fiscal year 2025. This represents a -3.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Enanta Pharmaceuticals, Inc's revenue growing?
Enanta Pharmaceuticals, Inc (ENTA) revenue declined by 3.4% year-over-year, from $67.6M to $65.3M in fiscal year 2025.
Is Enanta Pharmaceuticals, Inc profitable?
No, Enanta Pharmaceuticals, Inc (ENTA) reported a net loss of $63.2M over the trailing 12 months to June 30, 2026. In fiscal year 2025 it reported a net loss of $81.9M.
What is Enanta Pharmaceuticals, Inc's EBITDA?
Enanta Pharmaceuticals, Inc (ENTA) had EBITDA of -$80.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Enanta Pharmaceuticals, Inc's return on equity (ROE)?
Enanta Pharmaceuticals, Inc (ENTA) has a return on equity of -126.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Enanta Pharmaceuticals, Inc's free cash flow?
Enanta Pharmaceuticals, Inc (ENTA) recorded an outflow of $32.2M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Enanta Pharmaceuticals, Inc's operating cash flow?
Enanta Pharmaceuticals, Inc (ENTA) recorded an outflow of $19.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Enanta Pharmaceuticals, Inc's total assets?
Enanta Pharmaceuticals, Inc (ENTA) had $280.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Enanta Pharmaceuticals, Inc's capital expenditures?
Enanta Pharmaceuticals, Inc (ENTA) invested $12.9M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Enanta Pharmaceuticals, Inc spend on research and development?
Enanta Pharmaceuticals, Inc (ENTA) invested $106.7M in research and development during fiscal year 2025.
What is Enanta Pharmaceuticals, Inc's current ratio?
Enanta Pharmaceuticals, Inc (ENTA) had a current ratio of 4.21 as of fiscal year 2025, which is generally considered healthy.
What is Enanta Pharmaceuticals, Inc's liabilities-to-equity ratio?
Enanta Pharmaceuticals, Inc (ENTA) had a liabilities-to-equity ratio of 3.34 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
What is Enanta Pharmaceuticals, Inc's return on assets (ROA)?
Enanta Pharmaceuticals, Inc (ENTA) had a return on assets of -29.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Enanta Pharmaceuticals, Inc's P/E ratio?
Enanta Pharmaceuticals, Inc (ENTA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $339.0M as of Oct 23, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Enanta Pharmaceuticals, Inc's price-to-sales ratio?
Enanta Pharmaceuticals, Inc (ENTA) trades at 5.2x sales, its market capitalization divided by $65.3M revenue, trailing 12 months to June 30, 2026. The market capitalization is $339.0M as of Oct 23, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Enanta Pharmaceuticals, Inc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Enanta Pharmaceuticals, Inc (ENTA) held $188.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $19.3M over that year. Dividing the one by the other, the reported balance equals about 118 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Enanta Pharmaceuticals, Inc's Altman Z-Score?
Enanta Pharmaceuticals, Inc (ENTA) has an Altman Z-Score of -1.18, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Enanta Pharmaceuticals, Inc's Piotroski F-Score?
Enanta Pharmaceuticals, Inc (ENTA) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Enanta Pharmaceuticals, Inc's earnings high quality?
Enanta Pharmaceuticals, Inc (ENTA) reported a net loss of $81.9M while operations used $19.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Enanta Pharmaceuticals, Inc cover its interest payments?
Enanta Pharmaceuticals, Inc (ENTA) reported an operating loss of $85.3M against $7.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Enanta Pharmaceuticals, Inc?
Enanta Pharmaceuticals, Inc (ENTA) scores 64 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.